Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yincan Tongluo (银参通络胶囊) is an approved oral Traditional Chinese Medicine (TCM) capsule developed by Tianshan Pharmaceuticals (also known as Tiansheng Pharmaceutical Group) for the treatment of cardiovascular and cerebrovascular diseases. It is a nationally exclusive product in China, formulated as a solid TCM preparation. While the specific herbal composition and molecular targets are not detailed in public pipeline summaries, the drug is intended to improve blood circulation and address vascular conditions associated with the heart and brain. It is administered orally in capsule form and is part of the company's core portfolio of exclusive TCM products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yincan Tongluo.